Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most lethal gynecological cancer with few effective, targeted therapies. HGSOC tumors exhibit genomic instability with frequent alterations in the protein kinome; however, only a small fraction of the kinome has been therapeutically targeted in HGSOC. Using multiplexed inhibitor beads and mass spectrometry, we mapped the kinome landscape of HGSOC tumors from patients and patient-derived xenograft models. The data revealed a prevalent signature consisting of established HGSOC driver kinases, as well as several kinases previously unexplored in HGSOC. Loss-of-function analysi...
Source: Signal Transduction Knowledge Environment - February 17, 2020 Category: Science Authors: Kurimchak, A. M., Herrera-Montavez, C., Brown, J., Johnson, K. J., Sodi, V., Srivastava, N., Kumar, V., Deihimi, S., OBrien, S., Peri, S., Mantia-Smaldone, G. M., Jain, A., Winters, R. M., Cai, K. Q., Chernoff, J., Connolly, D. C., Duncan, J. S. Tags: STKE Research Articles Source Type: news
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet needs continue...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Prognosis of Stage IA Mixed Endometrial Carcinoma The Prognosis of Stage IA Mixed Endometrial Carcinoma
A study determines that the serous subtype may be associated with a poor prognosisin in uterine cancer.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 31, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Gene Expression Profiles Show Promise for Prognosis in Ovarian Carcinoma
Researchers compared primary high grade serous ovarian carcinoma tumors and their matched metastasis, showing evidence of separating the 2 sample types and potentially predicting patient survival. (Source: CancerNetwork)
Source: CancerNetwork - November 22, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models
(Impact Journals LLC) The cover for issue 62 of Oncotarget features Figure 7, 'Proposed model of the hyperploid pathway as a salvage survival strategy regulated by the G2-M checkpoint,' by Yeung, et al. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 19, 2019 Category: Cancer & Oncology Source Type: news
Changes in the metabolism of normal cells promotes the metastasis of ovarian cancer cells
(University of Chicago Medical Center) A systematic examination of the tumor and the tissue surrounding it -- particularly normal cells in that tissue, called fibroblasts -- has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a tumor type that primarily originates in the fallopian tubes or ovaries and spreads throughout the abdominal cavity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2019 Category: Cancer & Oncology Source Type: news
Building a Better Mouse Model for High-Grade Serous Carcinoma
Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
New Drug Combo Ups Survival in HER2/neu Uterine Serous Cancer
WEDNESDAY, April 18, 2018 -- For patients with human epidermal growth factor receptor 2 (HER2)/neu-positive uterine serous carcinoma, adding intravenous trastuzumab to treatment with carboplatin-paclitaxel is associated with increased... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2018 Category: Pharmaceuticals Source Type: news
Trastuzumab Effective in Uterine Serous Carcinoma (CME/CE)
(MedPage Today) -- In patients overexpressing HER2, a 5-month boost in PFS when added to carboplatin-paclitaxel (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 14, 2018 Category: Hematology Source Type: news
Does Trastuzumab Plus Carbo/Paclitaxel Up PFS in Advanced HER2+ Uterine Carcinoma?
At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Gynecologic Cancers News Conferences/SGO Source Type: news
Case: Metastatic Endometrial Serous Carcinoma to the Breast Case: Metastatic Endometrial Serous Carcinoma to the Breast
This unusual case underscores that while the breast is an atypical target of metastases, it is a possibility that needs to be considered, and should be confirmed histologically.Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Mutation in fallopian tube lesions may help catch ovarian cancer years earlier
(University of Pennsylvania School of Medicine) Screening for tumor cells in the fallopian tubes of women at high-risk for ovarian cancer may help detect the cancer years before it develops further, suggests a new study published online this week in Nature Communications. The new study traces the origins of high-grade serous ovarian carcinoma, the most frequent type of ovarian cancer that is often diagnosed at advanced stages, back to fallopian tube lesions known as 'p53 signatures' and serous tubal intraepithelial carcinomas (STICs) that harbor the TP53 gene mutations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2017 Category: Cancer & Oncology Source Type: news
Having More CD8+ Tumor-infiltrating Lymphocytes May Boost Ovarian Cancer Survival Having More CD8+ Tumor-infiltrating Lymphocytes May Boost Ovarian Cancer Survival
In women with high-grade serous ovarian carcinomas, increasing levels of CD8+ tumor-infiltrating lymphocytes (TILs) show a robust, dose-dependent survival benefit, according to a large observational study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 19, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - March 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers News Ovarian Cancer Conferences/SGO 2017 Source Type: news
Hormone Therapy Prolongs PFS in Low-grade Serous Cancer Hormone Therapy Prolongs PFS in Low-grade Serous Cancer
Hormone maintenance therapy prolongs progression-free survival, if not overall survival, in low-grade serous carcinoma following surgery and chemotherapy compared with routine observation alone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 27, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
